Biogen Idec 8-K 2017
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 10, 2017
(Exact name of registrant as specified in its charter)
225 Binney Street, Cambridge, Massachusetts 02142
(Address of principal executive offices; Zip Code)
Registrants telephone number, including area code: (617) 679-2000
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On June 10, 2017, Paul Clancy notified Biogen Inc. (the Company) that he will step down as Executive Vice President, Finance and Chief Financial Officer of the Company to join another biopharmaceutical company. Mr. Clancy will remain at the Company through the second quarter of fiscal 2017 and will assist with the transition.
On June 10, 2017, the Company appointed Gregory F. Covino, the Companys Vice President, Finance and Chief Accounting Officer, as the Companys interim Principal Financial Officer, effective upon Mr. Clancys departure. Mr. Covino will serve as the Companys interim Principal Financial Officer as the Company conducts a search for a new Chief Financial Officer.
Mr. Covino, age 51, has served as the Companys Vice President and Chief Accounting Officer since April 2012. Prior to that, Mr. Covino served at Boston Scientific Corporation, a medical device company, as Vice President, Corporate Analysis and Control Executive since March 2010, having responsibility for the companys internal audit function, and as Vice President, Finance, International from February 2008 to March 2010, having responsibility for the financial activities of the companys international division. Prior to that, Mr. Covino held several finance positions at Hubbell Incorporated, an electrical products company, including Vice President, Chief Accounting Officer and Controller from 2002 to 2008, Interim Chief Financial Officer from 2004 to 2005, and Director, Corporate Accounting from 1999 to 2002.
On June 13, 2017, the Company issued a press release announcing that Mr. Clancy will step down as Executive Vice President, Finance and Chief Financial Officer of the Company and the appointment of Mr. Covino as the interim Principal Financial Officer. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
The press release being furnished in this Item 7.01 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
The exhibit listed on the Exhibit Index below is furnished as part of this Current Report on Form 8-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 13, 2017